Author: Guru Singh

India’s $7.38 billion shrimp export industry stands at a crossroads during a defining period for the global seafood market, newly estimated at $71.87 billion in 2024 and headed for $105.35 billion by 2033. As fierce competition from Ecuador and escalating US tariffs threaten to rewrite industry norms, voices of authority like Guru Singh, Founder and…

The convergence of artificial intelligence and personalized medicine represents the most significant opportunity in biotech today, particularly for addressing the systematic gaps in women’s healthcare. This article explores how personalized medicine and AI in biotech are driving women’s healthcare innovation, highlighting biotech startups and AI-driven healthcare solutions that address critical gaps in the women’s health…

The global siRNA therapeutics market, now valued at $2.95 billion in 2024 and projected to reach $5.33 billion by 2030, tells the story of biotechnology’s most fascinating paradox: the challenge of perfect timing in innovation. This massive market growth masks a deeper truth about the industry’s earlier struggles with premature promise, as revealed by Dr.…

The global wound healing supplements market reached $3.2 billion in 2024, with growth projected at an 8.1% CAGR through 2032. New scientific findings demonstrate 50-60% faster wound recovery with innovative therapeutic approaches that address the root causes of tissue damage rather than just symptoms. Recent preclinical research led by prominent biotech innovators shows exceptional healing…

The global protein crisis is driving biotechnology companies to embrace insect processing as a breakthrough solution for sustainable protein production. With the global insect protein market valued at $1.17 billion in 2024 and projected to reach $5.53 billion by 2033, this emerging sector represents a $4.36 billion growth opportunity that merges advanced biotechnology R&D with environmental…

The biotechnology funding landscape operates on assumptions that recent insights are fundamentally challenging. A revealing conversation between Guru Singh, Founder and CEO of Scispot, and Negin Ashouri, CEO of FemTherapeutics, on the podcast talk is biotech! exposes the profound gap between what biotech founders expect from fundraising and what actually drives investor decision-making in biotech.…

India has emerged as the world’s largest buffalo meat exporter despite deep cultural reverence for cattle, creating a remarkable $5 billion industry that demonstrates how cultural nuance, regulatory sophistication, and operational excellence can generate extraordinary market opportunities. This comprehensive analysis examines how emerging biotechnology solutions intersect with traditional agri-export industries, offering strategic lessons for biotech…

The convergence of global agricultural insights and local innovation is reshaping India’s biotech landscape, particularly in the emerging field of insect technology. In a recent episode of talk is biotech! with Guru Singh, an illuminating conversation between Guru Singh, Founder and CEO of Scispot, and Praveen K Sappa, Founder & CEO of Arthro Biotech, revealed how…

The biotechnology sector stands at an unprecedented inflection point. With global biotech investments surging from $483 billion in 2024 to a projected $546 billion in 2025, the industry presents extraordinary growth opportunities across therapeutic areas from oncology to rare diseases. Yet beneath these promising headlines lies a persistent challenge that threatens to undermine the sector’s…

The biotechnology industry stands at a pivotal moment where artificial intelligence is fundamentally reshaping how companies approach drug discovery and development. In a recent episode of talk is biotech! with Guru Singh, featuring insights from Guru Singh, Founder and CEO of Scispot, and Negin Ashouri, CEO of FemTherapeutics, industry leaders explored how biotechnology companies are increasingly…

In a revealing conversation on “talk is biotech! with Guru Singh,” two industry veterans unveiled a transformative approach that could reshape therapeutic development strategies and unlock unprecedented opportunities in cancer prevention pharmaceuticals. The discussion between Guru Singh, Founder and CEO of Scispot (a leading AI platform that helps over 100 biotechs collect, clean, and activate their data…

The transformative impact of artificial intelligence on agricultural biotechnology is reshaping how scientific research is conducted, analyzed, and applied across the industry. The life sciences industry stands at an unprecedented inflection point where artificial intelligence is fundamentally transforming how scientific work is conceptualized, executed, and delivered. This transformation is particularly pronounced within agriculture biotech companies…

The pharmaceutical industry stands at an unprecedented crossroads where traditional methodologies are being revolutionized by cutting-edge innovations. For biotech startups, this transformation represents not just an operational shift, but a fundamental reimagining of how drug discovery and development can be approached in the modern era. Recent insights from leading industry experts, including discussions featured on…

The convergence of artificial intelligence and personalized medicine represents the most significant opportunity in biotech today, particularly for addressing the systematic gaps in women’s healthcare. This article explores how personalized medicine and AI in biotech are driving women’s healthcare innovation, highlighting biotech startups and AI-driven healthcare solutions that address critical gaps in the women’s health…

The decision of where to establish and scale a biotechnology startup represents one of the most consequential strategic choices facing entrepreneurs in the life sciences sector, particularly when considering access to biotech startup funding. Recent insights from an interview between Guru Singh, Founder and CEO of Scispot, and Negin Ashouri, CEO of FemTherapeutics, on the…

The journey of a biotech startup from Iran to Canada often starts with a well-planned path. However, some of the most inspiring entrepreneurial stories arise from unexpected changes. In a compelling episode of talk is biotech! with host Guru Singh, Negin Ashouri, CEO of FemTherapeutics, shares how political upheaval redirected her original plan from the…

The biotechnology industry stands at a transformative moment where female founders in biotech are systematically dismantling traditional barriers and pioneering breakthrough innovations in healthcare, driving women’s health innovation forward. This paradigm shift represents more than demographic diversification. It signals a fundamental reimagining of how medical innovation addresses historically underserved patient populations through fresh perspectives and…

The biotechnology sector is experiencing a paradigm shift driven by AI for genomics and personalised medicine, sustainability imperatives, and manufacturing innovations that will fundamentally reshape how companies approach research, healthcare delivery, and global production systems over the next decade. Recent insights from industry leaders interviewed by Guru Singh, Founder and CEO of Scispot and host…

The global biotech industry faces an unprecedented challenge in balancing innovation requirements with capital efficiency demands. While venture funding contracts and R&D expenses escalate, a strategic opportunity emerges from an unexpected source. Recent insights from “talk is biotech! with Guru Singh” reveal compelling evidence that biotech startups in Canada possess a substantial 50% cost advantage…

The emergence of insect tech startups in 2025 represents a transformative shift in how biotechnology founders approach sustainability challenges, converting waste streams into valuable revenue opportunities while addressing global protein security concerns. Recent insights from the interview between Guru Singh, Founder and CEO of Scispot, and Praveen K Sappa, CEO of Arthro Biotech, featured on…

Embracing Two Forms of Intelligence: Early-stage biotech founders today stand at a crossroads between two powerful paradigms of innovation: artificial intelligence (AI) and nature’s own organic intelligence. Guru Singh, Founder and CEO of Scispot, a company providing a GenAI-powered lab technology stack for life science labs, recently sat down with Praveen K Sappa, CEO of…

Scispot, a leading provider of AI-powered solutions for life science laboratories, continues to drive innovation at the forefront of biotechnology. In a recent episode of “talk is biotech!” podcast, Scispot’s Founder and CEO Guru Singh engaged in an insightful conversation with Negin Ashouri, CEO of FemTherapeutics, exploring how cutting-edge technology and artificial intelligence are revolutionizing…

Early-stage biotech founders are navigating a rapidly evolving healthcare landscape where precision medicine is emerging as a game-changer. In a recent episode of talk is biotech! featuring host Guru Singh and guest Negin Ashouri, the conversation centered on why the future of medicine isn’t one-size-fits-all. Guru Singh, Founder and CEO of Scispot, brings extensive expertise…

Twenty years ago, sequencing a human genome cost billions of dollars and synthesizing a gene was painstakingly slow and expensive. Today, those barriers have crumbled. “The cost of DNA sequencing and synthesis has dropped exponentially over the past two decades, democratizing innovation in biotech,” says Kevin Chen, Co-Founder and CEO of Hyasynth Bio, a pioneering…

In a recent episode of talk is biotech!, Singh interviewed Kevin Chen, co-founder and CEO of Hyasynth Bio, to explore a critical question: what makes synthetic biology startups successful? Kevin Chen, a biotechnology entrepreneur with extensive experience in synthetic biology and fermentation technologies, has led Hyasynth Bio from concept to commercialization, making it one of…

Scispot, a leading provider of AI-powered laboratory management solutions for life science organizations, has established itself as a key player in biotech innovation infrastructure. The company’s founder and CEO, Guru Singh, leverages his deep expertise in biotech entrepreneurship by hosting the popular podcast “talk is biotech!” where he explores the latest trends, challenges, and opportunities…

In a recent episode of talk is biotech!, a podcast produced by Scispot, host Guru Singh sat down with Negin Ashouri, CEO of FemTherapeutics, to explore a silent crisis in women’s health and an innovative solution. Guru Singh, who serves as Founder and CEO of Scispot, brings extensive expertise in biotech innovation to the podcast.…

In a new episode, Guru Singh, Founder and CEO of Scispot, a pioneering AI-driven lab automation platform for life science labs, spoke with Kevin Chen, Co-Founder and CEO of Hyasynth Bio, a synthetic biology company focused on innovative protein design. Their discussion centered on how artificial intelligence is transforming the way scientists design proteins, effectively…

The Rise of a New Synbio Era In a recent episode of talk is biotech!, a podcast hosted by Guru Singh, Founder and CEO of Scispot, featuring discussions with biotech entrepreneurs including Kevin Chen, Co-Founder and CEO of Hyasynth Bio, a pioneering biotech company focused on producing cannabinoids in yeast, the two biotech entrepreneurs discussed…

Every minute, another hysterectomy is performed in the United States. For decades, women facing pelvic health issues like pelvic organ prolapse or incontinence have often been presented with two daunting options: undergo invasive surgery (such as a hysterectomy or a mesh implant repair) or manage symptoms with decades-old devices known as pessaries. Both paths exemplify…

In a recent episode of talk is biotech! with Guru Singh, founder and CEO of Scispot, an illuminating metaphor emerged: synthetic biology is like building with LEGO. Singh, who leads Scispot (often described as “the best tech stack for biotech”), has built an AI-driven platform that helps over 100 life science startups manage and supercharge…

Lung cancer remains the leading cause of cancer-related deaths worldwide. However, a new wave of therapies is expanding options for patients, driven by personalized medicine and innovative science. New treatments for lung cancer include a growing number of targeted therapies and new forms of immunotherapy, according to leading oncologists at major cancer centers. Many emerging…

Guru Singh, the founder and CEO of Scispot and host of the podcast talk is biotech!, recently interviewed Kevin Chen, the CEO of Montreal-based Hyasynth Bio, on the show. They discussed a surprising catalyst for professional networking: personal passion. Kevin’s journey shows how genuine enthusiasm for science, especially in biology and conservation, can lead to…

In a recent talk is biotech! podcast interview, biotech CEO Kevin Chen outlined what he would do with “unlimited funding” – and his answer was surprisingly pragmatic. Instead of fantasizing about moonshots, Chen emphasized investing in talent, focusing on high-impact research, and allocating funds with precision. He would generously compensate scientists and target specific industry…

Scispot, a leading provider of AI-driven digital infrastructure for life science labs, also produces the popular podcast “talk is biotech!”. The podcast recently featured an insightful conversation between Guru Singh, CEO of Scispot, and Kevin Chen, co-founder and CEO of Hyasynth Bio, a pioneering biotech company focused on producing cannabinoids using synthetic biology. In this…

Canada stands at a crossroads in biotechnology and artificial intelligence. Despite possessing world-class scientific talent and innovation capabilities, the country has yet to emerge as a global powerhouse in these transformative sectors. This challenge was recently explored in depth during a talk is biotech! podcast interview featuring Guru Singh, Founder and CEO of Scispot (a…

In a recent episode of the talk is biotech! podcast, host Guru Singh sat down with Kevin Chen to explore a provocative question: Can biotech innovation move at software speed? Guru Singh, the Founder and CEO of Scispot, brings deep expertise in biotech digitization through his company’s AI-driven technology stack designed specifically for life science…

Introduction: New Innovation Landscape In a recent episode of talk is biotech! (a podcast hosted by Scispot CEO Guru Singh), the conversation spotlighted a profound shift in biotechnology innovation. Kevin Chen, Co-Founder and CEO of Hyasynth Bio and President of SynBio Canada, described the one trend he’s betting his career on: the power of diverse…

In a recent episode of talk is biotech! with Guru Singh, the discussion centered on what it takes to build a billion-dollar tech company, a theme highly relevant to biotech founders and investors. Guru Singh, Founder & CEO of Scispot (an AI-powered “Lab Operating System” that integrates data and automation for life science labs), opened…

Genomics will transform how we live, from preventing diseases to improving food security and fighting climate change for a better world. This bold vision, articulated by Ivan Liachko, Founder and CEO of Phase Genomics, frames the promise of modern genomics. In a recent episode of the “talk is biotech!” podcast, Guru Singh, Founder and CEO…

In a recent episode of the talk is biotech! podcast, Guru Singh, Founder and CEO of Scispot, and Kevin Chen, CEO of Hyasynth Bio, discussed a striking paradox in today’s startup landscape. Thanks to advanced AI and no-code tools, getting a product off the ground has never been easier, yet sustaining and scaling a business…

In the global race to harness biotechnology for economic and societal gain, Canada stands at a crossroads. The country boasts world-class research output and scientific talent, yet struggles to translate these strengths into commercial success. As Guru Singh, Founder and CEO of Scispot (a company that helps over 100 BioTechs collect, clean, and activate their…

Scispot, a leading lab informatics company offering AI-driven tech stack for life science labs, recently spotlighted a vital ingredient for biotech startup success: mentorship. In a talk is biotech! podcast conversation, Scispot’s founder Guru Singh (whose very name means “teacher”) chatted with Kevin Chen, CEO of Hyasynth Bio, about why guidance from experienced mentors is…

The biotechnology industry is undergoing a rapid transformation driven by technological advances and a democratization of science. Guru Singh, founder and CEO of Scispot, a company providing the best tech stack for modern biotech labs, recently discussed these changes with Kevin Chen, CEO of Hyasinth Bio, a pioneer in engineering yeast to produce cannabinoids, on…

In a recent episode of the talk is biotech! podcast, Scispot‘s founder and CEO Guru Singh spoke with Kevin Chen, co-founder and CEO of Hyasynth Bio and President of SynBio Canada, about the changing landscape of biotechnology entrepreneurship. Chen’s personal journey, from skipping the traditional PhD path to joining the world’s first synthetic biology accelerator, illustrates…

Bacteriophages, viruses that infect and destroy bacteria, are emerging from obscurity to become a hotbed of biotech innovation. Scispot, known for providing the best AI stack for life science labs, recently spotlighted this trend on its talk is biotech! podcast. In a conversation between Scispot’s founder Guru Singh and Ivan Liachko (CEO of Phase Genomics),…

In a recent episode of talk is biotech!, Guru Singh, hosted a fascinating conversation with Dr. Ivan Liachko, CEO and co-founder of Phase Genomics, about bacteriophage therapy, a century-old approach using viruses to kill bacteria. Guru Singh, a molecular biologist-turned-entrepreneur who established Scispot in 2020 with a mission to accelerate biotech R&D through AI-powered lab informatics solutions after a…

In a recent talk is biotech! podcast episode, Guru Singh (Founder and CEO of Scispot, a laboratory technology platform with AI capabilities) sat down with Kevin Chen, Co-Founder and CEO of Hyasynth Bio, to discuss what it really takes to build a biotech startup from the ground up. Scispot, founded by Guru Singh, is known…

Guru Singh, Founder and CEO of Scispot, recently sat down with Kevin Chen, CEO of Hyasynth Bio, on the podcast talk is biotech! to discuss what it means to build a career driven by passion and purpose. The conversation explored how turning work into “play” can energize us, whereas misaligned jobs leave us drained. Singh’s…

Scispot, known for its AI-driven tech stack for biotech labs, recently hosted an eye-opening conversation on the talk is biotech! podcast. Guru Singh (Founder and CEO of Scispot) spoke with Kevin Chen, CEO of Hyasynth Bio, about a bold question: Can cannabinoids like THC and CBD make the world happier by improving mental health? Chen’s…

Executive Summary Antibiotic Resistance as a Looming Crisis: Antimicrobial resistance (AMR), especially antibiotic resistance in “superbugs,” is emerging as the next potential pandemic-level threat. It already claims an estimated 1.27 million lives annually (2019) and is associated with nearly 5 million deaths worldwide, a toll higher than HIV or malaria. If current trends continue, AMR…

In the high-stakes world of biotechnology startups, success often hinges as much on psychology and leadership as on scientific brilliance. The journey from lab bench discovery to a scalable biotech enterprise is a marathon marked by uncertainty, setbacks, and the need for unwavering conviction. Guru Singh, the founder and CEO of Scispot (a company known…

In a recent “talk is biotech!” podcast, host Guru Singh, Founder and CEO of Scispot, sat down with Kevin Chen, CEO of Hyasynth Bio, to explore an audacious idea: Could everyday kitchens one day house personal bioreactors? Scispot, known for providing the best AI-driven tech stack for life science labs, is at the forefront of…